Ascenion is looking forward to a reunion with industry decision makers, venture capitalists, academic inventors and entrepreneurs. Eight from a total of 65 projects to be featured originate from Ascenion’s academic partners.

dentalXrai and Tube Pharmaceuticals were both acquired by international key players in their respective fields. The transactions add new momentum, development and marketing power to the start-ups’ projects.

Ascenion supports spin-offs from their partner institutes on their long-term growth trajectory. Recently, four of our portfolio companies have received different awards and prizes – sincere congratulations!

Through its spin-off program, Helmholtz Enterprise finances the establishment of start-up teams and the implementation of start-up projects in the Helmholtz Association.

Leopard Biosciences GmbH, founded in July, is developing a new diagnostic platform that can detect multiple markers in a single test. The translation of the technology was made possible by funding from the Helmholtz Association.

Ten female-led startups competed in the finale of the Female StartAperitivo startup competition. Ascenion’s portfolio company TimeTeller received the most votes in the public ballot for a method to make chemotherapy more effective and less harmful to the patient.

Ascenion's portfolio company OMEICOS has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) to co-finance a Phase 2a study evaluating their lead product candidate OMT-28 in Primary Mitochondrial Disease (PMD) patients.

The Berlin start-up develops AI-based software for predicting complications after major cardiac surgery. New business angels and family offices have now invested in the company, alongside the existing investor consortium around IBB Ventures.

Bio^M and Sweden’s SmiLe Incubator are once again holding their annual BioTech Bootcamp. This free, international training programme is aimed at aspiring entrepreneurs in the field of medical biotechnology.

A record number of over 270 innovators from academia and industry came together in Munich for this year’s BioVaria, one of Europe’s leading events boosting partnerships for the transfer of life-science inventions into application.

Ascenion is looking forward to a reunion with industry decision makers, venture capitalists, academic inventors and entrepreneurs. Eight from a total of 56 projects to be featured originate from Ascenion’s academic partners.

The investment round is led by TRUMPF Venture with the objective of translating iThera Medical’s optoacustic imaging technology into routine clinical use.

Recovery Cat has developed software to improve the care of around six million patients in Germany with severe mental disorders. The investors are IBB Ventures’ Impact Fonds, Springboard Health Angels and a family office from Heidelberg.

Bioventure and IFB Innovationsstarter GmbH are financing the Hamburg biotech company for the next four years – to build the necessary infrastructure for research and production.

Ascenion’s portfolio company has dosed the first patient with its lead candidate TK-8001, a new therapy to target MAGE-A1 positive solid tumours.

With the new round of funding, Aignostics aims to continue growing their team, putting a stronger focus on the US market, and accelerating their investment into their platform and regulatory excellence.

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections.

The financing round was supported by a selected network of investors from medical and financial sectors. It enables the start-up to advance its fully automated ‘lab-in-a-box’ system for the molecular diagnosis of skin diseases to the market.

The company will use the proceeds to advance its groundbreaking optoacoustic imaging technology into clinical practice. If successful, it would provide a superior, non-invasive alternative to established diagnostic procedures in many diseases.

25 August 2021, Munich – Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by…

The start-up has also been certified as a medical device manufacturer in the EU. Its x-c-bleeding product uses AI-based software to predict the risk of post-operative bleeding in patients in intensive care units.

The start-up has dosed the first participant in a Phase I study with its lead candidate HRX-0215. The small molecule holds strong potential to restore the liver’s natural capacity to regenerate itself, both in acute and chronic liver disease.

Initiation of the IMAGE1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in Q4 2021

The Berlin start-up uses AI to recognize post-operative complications before they become critical. IBB Ventures and several business angels have invested in the company.

BioVaria Startup Awards go to iRASP Therapeutics and OrganoTherapeutics

Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.

HepaRegeniX has demonstrated proof-of-efficacy in acute liver disease in preclinical studies performed in collaboration with the University Hospital of Tübingen (Germany) and the Mayo Clinic (Rochester, MN, USA).

Newly founded dentalXrai provides a unique, AI-based platform to improve and speed up the analysis of dental X-ray images. Ascenion, technology transfer partner of the Charité – Universitätsmedizin Berlin, holds equity in the start-up.

Diffratec, a spin-off from the Medical University of Innsbruck (MUI), commercializes breakthrough diffractive elements. These elements, in particular Moiré lenses, are extremely compact and tunable with high speed and precision.

Ascenion and Innovationsstarter Fonds Hamburg acquire equity in Hamburg start-up – innovative therapeutic approach enters clinical testing

Only a few places left! Register now for the 13th Biotech NetWorkshop, 5–7 February 2020 in Schloss Ringberg.

Don’t miss your chance to secure a spot at next year’s BioVaria, 27 – 28 April 2020 in Munich! Application for European startups is now open until 14^t…

Should public research institutes and universities receive equity in start-ups founded to commercialize their intellectual property? And if so, how…

Ascenion’s portfolio company Berlin Cures has initiated a Phase IIa clinical study with its lead compound BC 007. The two-armed, randomized,…

Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products…

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international…

Ascenion’s portfolio company OMEICOS dosed a first patient in a Phase II clinical trial for its lead program OMT-28. The placebo-controlled,…

This is an exciting opportunity for European healthcare entrepreneurs, start-ups and SMEs: EIT Health invites you to apply for participation in the…

Technology sneak peek from Ascenion: Seven breakthrough life-science inventions                                      

12 March 2019, Munich, Germany…

BioVaria is organised by Ascenion and several other technology transfer organisations from all across Europe. The conference brings together Europe’s…

Clinicians and scientists from the Medical University Innsbruck (MUI) and the University of Innsbruck have developed an innovative urine test to…

Don’t miss your chance to secure a spot at next year’s BioVaria, 8 - 9 May 2019 in Munich! Application for European startups is now open until 1^st…

iThera Medical, a spin-off from the Helmholtz Zentrum München, has closed series C financing with new investors FLUXUNIT, the corporate venture…

In April, the members of the rapidly growing TechnologieAllianz e.V. teamed up with founders, investors, scientists and politicians for the 3rd…

This year’s BioVaria was the event in 2018 for early-stage, life-science European startups to connect with investors, with a record number of company…

Startup Awards go to OPSYON and LIfT Biosciences

26 April 2018, Munich, Germany – Over 250 innovative minds gathered in Munich on April 23-24 for the…

Berlin Cures, one of Ascenion’s portfolio companies, has announced positive Phase I results for its lead candidate BC007 for the treatment of heart…

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international…

Join over 400 experts in medical innovation to discuss global challenges and pioneering technologies in healthcare. During two conference days, you…

Technology sneak peek from Ascenion: Five breakthrough life-science inventions

9 March 2018, Munich, Germany – On 23–24 April 2018, decision makers…

Don’t miss your chance to secure a spot at BioVaria on 23./24. April 2018 to pitch your company to leading investors and biopharmaceutical decision…

Around thirty startup founders and aspiring entrepreneurs met in Munich during this year’s Biotech NetWorkshop to learn from drug development experts…

BioVaria Spin-off Awards go to Captain T Cell and Provirex

24 May 2017, Munich, Germany – On 22–23 May 2017, over 180 innovative minds gathered in…

Join Europe’s leading showcase for life-science inventions!

Ascenion is proud to present a strong line-up of speakers, participants and technologies…

Network with your peers, seasoned entrepreneurs and industry experts to gain valuable feedback on how to improve your project’s chances of success in…

Technology Sneak Peek from Ascenion: Human T-cell receptors for cancer therapy

4 April 2017, Munich, Germany – On 22-23 May 2017, dealmakers from…

This year’s BioVaria Anniversary Edition will, for the first time, extend over two days and include the promising field of digital health. Top-tier…

Around 40 commercially attractive, licensable technologies that were presented at this year’s BioVaria are now available online – including videos of…

BioVaria Spin-off Awards go to Charité spin-off and Braingineering Technologies

19 May 2016, Munich, Germany – Dealmakers and investors from the…

Join Europe’s leading market place for life-science inventions!

Ascenion unveils technology highlights: New approaches for the treatment of neurodegenerative disorders and glioblastoma

BioVaria is designed for dealmakers and investors from the global life-science sector responsible for identifying, licensing or funding break-through…